An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
|Videos|June 9, 2021
Oncology Space Provides Dynamic Opportunities for Research Pharmacists
In an interview with Pharmacy Times, Brian Wortz, PharmD, said he enjoys the innovation in his research, especially when their findings have the potential to drastically impact patients’ lives.
Advertisement
In his work with Cancer Treatment Centers of America, research pharmacist Brian Wortz, PharmD, specializes in oncology clinical research. In an interview with Pharmacy Times, Wortz said he enjoys the innovation in his research, especially when their findings have the potential to drastically impact patients’ lives.
Advertisement
Related to this article
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5